Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations (NCT07598357) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations
United States40 participantsStarted 2026-06
Plain-language summary
The purpose of this study is to prospectively study the safety of salvage red blood cell (sRBC) transfusion during pancreatic surgery.
Primary Objective:
1. To summarize rates and timing of septic adverse events (AE) for patients who receive sRBC or aRBC transfusions within 72 hours of peri-operative transfusion.
2. To summarize rates and timing of transfusion related AEs for patients who receive sRBC or aRBC transfusions within 72 hours of peri-operative transfusion.
3. To summarize rates and timing of AEs in the first 7 post-operative days.
Secondary Objectives:
1. To summarize the number of units of aRBC transfused post operative day (POD) #0 after sRBC transfusion in the operating room.
2. To summarize the number of units of aRBC transfused POD#1-7 after sRBC transfusion the operating room, in the absence of overt post-operative hemorrhage.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Provision of signed and dated informed consent form. Able to understand their disease and the exploratory nature of sRBC transfusion during surgery for this histology.
. Patient is 18 years of age or older
. Patient has a diagnosis of cytologically or pathologically confirmed pancreatic adenocarcinoma
. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
. Patient has an American Society of Anesthesiologists (ASA) classification of physical health status of 1-4
. Life expectancy of greater than six months
. Hemoglobin \> 8.9 g/dl
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Rate of sepsis within 72 hours of operations
Timeframe: within 72 hours of operations
2
Rate of transfusion related complication within the first 72 hours
Timeframe: Up to 7 days post-operative
3
Rate of all adverse events in the first post-operate week
. Concomitant medical problems that would place the patient at unacceptable risk for a major surgical procedure.
. History of congestive heart failure and/or an LVEF \<40%.
. Metastases
. Active systemic infections, hematological diseases, coagulation disorders or other major medical illnesses of the cardiovascular, hepatic, renal, respiratory or immune system.
. Patients with transabdominal drains, or peripancreatic abscess or fluid collections on cross-sectional imaging.